DR. ALAN SAVEN, M.D.
Osteopathic Medicine at Torrey Pines Rd, La Jolla, CA

License number

California A42979

Organization information

See more information about ALAN SAVEN at bizstanding.com

Scripps Health - Alan Saven MD

10666 N Torrey Pne Rd, La Jolla, CA 92037

Categories:

Oncology Physicians & Surgeons

Phone:

(858) 554-5269 (Phone)

Professional information

Dr. Alan Saven, La Jolla CA - MD (Doctor of Medicine)

Specialties:

Hematology, Medical Oncology, Oncology

Address:

10666 N Torrey Pines Rd #STE MS 217, La Jolla 92037
(858) 554-9489 (Phone)

Certifications:

Hematology, 1990, Internal Medicine, 1987, Medical Oncology, 1989

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

10666 N Torrey Pines Rd #STE MS 217, La Jolla 92037
Scripps Green Hospital
10666 North Torrey Pines Rd, La Jolla 92037
Scripps Memorial Hospital La Jolla
9888 Genesee Ave, La Jolla 92037
Sunrise Hospital and Medical Center
3186 South Maryland Pkwy, Las Vegas 89109

Education:

Medical School
University Of Cape Town, Faculty Of Health Sciences
Graduated: 1982
Groote Schuur Hospital
Graduated: 1983
Albert Einstein Med Center
Graduated: 1986
Scripps Clin
Graduated: 1987

Alan Saven, La Jolla CA

Specialties:

Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology, Hematology

Work:

Scripps Green Hospital
10666 N Torrey Pines Rd, La Jolla, CA 92037

Education:

University Of Cape Town (1982)

Method For Preventing Restenosis Using A Substituted Adenine Derivative

US Patent:

6239118, May 29, 2001

Filed:

Oct 5, 1999

Appl. No.:

9/412418

Inventors:

Richard A. Schatz - Rancho Santa Fe CA
Alan Saven - San Diego CA

International Classification:

A61K 3170

US Classification:

514 45

Abstract:

The present invention discloses a method for the prevention of atherosclerosis, its genesis, progression and restenosis in human patients undergoing treatments for arterial lesions such as PTA or atherectomy, and which may be accompanied by stent implantation. Further, the treatment method disclosed has applicability in all stages of atherosclerosis in which monocytes play a role. The compound utilized in the present method as the active agent is a 2-halo-2'-deoxyadenosine such as 2-chloro-deoxyadenosine (2-CdA). The treatment method of the present invention includes the administration of 14 doses of 2-CdA in the amount of 0. 12 mg/kg. One dose is given intravenously before the coronary intervention, another is given intravenously after the intervention and the remaining twelve doses are given subcutaneously at weekly intervals over a subsequent three month period.

2-Halo-2'-Deoxyadenosine Treatment For Histiocytosis

US Patent:

5510336, Apr 23, 1996

Filed:

Sep 6, 1994

Appl. No.:

8/301243

Inventors:

Alan Saven - San Diego CA
Lawrence D. Piro - La Jolla CA

International Classification:

A61K 3170

US Classification:

514 46

Abstract:

An improved method for treating Class I histiocytosis, Langerhans cell histiocytosis, is disclosed. In accordance with that method, a therapeutically effective amount of a 2-halo-2'-deoxyadenosine is administered to a host mammal such as a human patient having histiocytosis in an amount of about 0. 5 to 0. 9 mg/kg of body weight over a course of about 5 to 9 days for up to two courses.

2-Halo-2'-Deoxyadenosines As Therapeutic Agents Against Malignant Astrocytoma

US Patent:

5424296, Jun 13, 1995

Filed:

Apr 15, 1993

Appl. No.:

8/048111

Inventors:

Alan Saven - San Diego CA
Lawrence D. Piro - La Jolla CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 3170

US Classification:

514 46

Abstract:

A process for the treatment of malignant astrocytoma in mammals is disclosed that utilizes a 2-halo-2'-deoxyadenosine derivative as the active treating agent.